Valuation : Bolt Biotherapeutics, Inc.

Market Cap 7.35M 6.34M 5.95M 5.43M 10.22M 701M 10.27M 70.49M 27.52M 354M 27.59M 26.99M 1.18B P/E 2026 *
-0.16x
P/E 2027 * -0.19x
Enterprise Value 7.35M 6.34M 5.95M 5.43M 10.22M 701M 10.27M 70.49M 27.52M 354M 27.59M 26.99M 1.18B EV / Sales 2026 *
36.7x
EV / Sales 2027 * 2.1x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 day-4.62%
1 week+4.09%
Current month-4.39%
1 month-5.10%
3 months-28.02%
6 months-15.60%
Current year-30.23%
1 week 3.65
Extreme 3.65
4.27
1 month 3.13
Extreme 3.13
4.27
Current year 3.13
Extreme 3.13
7.2
1 year 3.13
Extreme 3.13
7.2
3 years 3.13
Extreme 3.13
31.2
5 years 3.13
Extreme 3.13
385.7
10 years 3.13
Extreme 3.13
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap.
10/06/26 Free

Chairman

5,000 0.2602%
28/01/26 Free

Chief Operating Officer

10,000 0.5210%
28/01/26 Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
-4.62%+4.09%-28.02%-82.82% 7.35M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.28%-1.32%+50.57%+164.88% 28.19B
Weighted average by Cap. -1.93%-1.50%+57.15%+152.82%

Financials

2026 *2027 *
Net sales 200K 173K 162K 148K 278K 19.08M 279K 1.92M 749K 9.65M 751K 734K 32.01M 3.5M 3.02M 2.83M 2.59M 4.87M 334M 4.89M 33.57M 13.11M 169M 13.14M 12.85M 560M
Net income -47.4M -40.92M -38.36M -35.02M -65.89M -4.52B -66.21M -455M -178M -2.29B -178M -174M -7.59B -47.5M -41.01M -38.44M -35.1M -66.03M -4.53B -66.35M -456M -178M -2.29B -178M -174M -7.6B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
28/08/26 $3.815 -4.62% 24,986
27/08/26 $4.000 +2.04% 7,708
26/08/26 $3.920 +1.82% 3,750
25/08/26 $3.850 +2.94% 2,389
24/08/26 $3.740 +2.05% 11,125
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
3.815USD
Average target price
29.00USD
Spread / Average Target
+660.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock